Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
284
resultados
Última actualización
11/05/2026 [08:29:00]
Resumen de: AU2026202803A1
The present invention is directed to assay methods and compounds and kits used in such assays. pr p r
Resumen de: US20260126430A1
0000 Provided herein are compositions and methods for real-time identification and isolation of base-edited cell populations. Also provided herein are methods for producing enriched isogenic lines of genetically modified cells, including base-edited human pluripotent stem cells. In particular, provided herein are methods utilizing transient expression of reporter proteins, the detectable signal of which is altered following base editing. Using the transient reporter with a base editor permits enrichment of isogenic populations of base-edited cells.
Resumen de: WO2026096493A1
The present disclosure provides methods of diagnosing, characterizing, or treating diseases (e.g., Alzheimer's Disease) associated with phosphorylated tau proteins, including p-tau217 and p-tau243, in subjects in need thereof.
Resumen de: US20260126456A1
A method of detecting ASC specks in a patient sample generally includes labeling a patient sample of cerebrospinal fluid with an anti-ASC antibody and detecting the anti-ASC antibody, thereby detecting the ASC specks in the patient sample. The method may be used to determine the risk of the patient having a neurodegenerative disorder or an inflammatory disorder.
Resumen de: WO2026093448A1
The invention relates to a single domain antibody that binds Heparin-binding EGF-like growth factor (HB-EGF) for use in preventing, treating and/or diagnosing e.g. a brain disease, wherein the single domain antibody is in combination with a therapeutic compound and/or a diagnostic/imaging compound. The single domain antibody may in particular be a Variable domain of a Heavy chain only (VHH) antibody of camelid origin or an engineered single-domain antibody (sdAb) of other mammalian and be capable of transporting cargo such as peptides or other molecules into the brain across the blood-brain barrier (BBB) by receptor-mediated transcytosis (RMT). The brain disease may for example be Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, brain tumor, or Hunter syndrome.
Resumen de: US20260126444A1
The present invention relates to a method for in vitro diagnosis of Long COVID in a subject, wherein the method comprises the following steps: a) providing a biological sample obtained from the subject; b) measuring the levels of at least one protein in said sample, wherein the at least one protein is selected from Autophagy Related 4B Cysteine Peptidase (ATG4B), Mitofusin 2 (MFN2), Dynamin-related Protein 1 (DRP1), and/or Superoxide dismutase 1 (SOD1); and c) comparing the levels of the at least one protein measured in step b) with a respective reference, wherein an increase in the levels of the at least one protein in said sample relative to the reference is indicative of Long COVID diagnosis.
Resumen de: US20260126434A1
0000 The disclosure relates to methods and kits for detecting, quantifying, or both, phosphorylated tau (p-tau) in a biological sample. The disclosure further provides methods for detecting brain-associated tau polypeptide, a brain injury or a neurodegenerative disease in a subject, determining the eligibility of individuals for participation in clinical trials for brain injury and/or neurodegenerative disease treatments, distinguishing between individuals with brain injury and/or neurodegenerative disease and without brain injury and/or neurodegenerative disease, and monitoring response to treatment of the same.
Resumen de: AU2025205760A1
Provided herein are methods for interrogating interactions between a binding molecule and a polypeptide of interest using hydrogen-deuterium exchange mass spectrometry, optionally in combination with in silico modelling of the binding interaction between the binding molecule and the polypeptide. The polypeptides of interest that are interrogated in a disordered domain include, without limitation, androgen receptor polypeptides, alpha-synuclein polypeptides, p27 polypeptides, c-myc polypeptides, and Tau polypeptides. Further described herein are enrichment of molecules that bind to a polypeptide described herein with high affinity, as well as methods of treating diseases or conditions by administering a binding molecule described herein to a subject in need thereof.
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: US20260125418A1
The invention relates to a compound of the formula Xm—(Y-L-T)n and a method for the detection or prognosis of a disease in the exhaled breath of a subject. X, when present is a moiety operable to target the compound to a site of interest in vivo; m is (or at least 1, Y is a cleavable group; L is a self-immolative linker, T is a terminating moiety, and n is 1 when m is 0 or n is at least 1 when m is at least 1, L is a self-immolative linker. The terminating moiety, T, may comprise an isotopically labelled reporter molecule or a precursor thereof. The reporter molecule is operable to be released upon cleavage of the cleavable group, Y; and the reporter molecule, upon release, is a volatile compound.
Resumen de: US20260126455A1
0000 Methods and dosing regimens using alpha 7 acetylcholine nicotine receptor binding agents are provided to prevent or inhibit intracellular accumulation of amyloid in cells leading to inhibition or prevention of neuronal cell death. In addition, these methods and dosing regimens are coupled with methods and dosing regimens to reduce and/or prevent blood-brain barrier leakage of vascular-derived amyloid into the brain and/or methods and dosing regimens to reduce and/or prevent neuroinflammation to prevent and/or inhibit the progression of Alzheimer's disease and other forms of dementia and mild cognitive impairment. Also provided are methods for identifying individuals for this treatment.
Resumen de: US20260125460A1
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: US20260126454A1
Provided herein is a sensitive, quantitative, and scalable targeted proteomics assay of Alzheimer's Disease biomarkers representing neuronal, glial, vasculature and metabolic pathways. The biomarkers are protease-digested peptides selected from biological samples of individuals having normal Aβ and Tau levels (AT−) and from symptomatic and asymptomatic individuals having low Aβ and high Tau levels (AT+). The assay uses selective reaction monitoring-based mass spectrometry (SRM-MS) of peptides in the biological samples after digestion.
Resumen de: EP4737902A1
0001 The present invention relates to a composition for diagnosing Parkinson's disease, comprising an agent for detecting a protein consisting of a combination of GLUT3 and any one or more selected from the group consisting of USP14, α-synuclein, and AIMP2, or a gene encoding the protein. The composition for diagnosing Parkinson's disease and a diagnostic kit comprising the composition, of the present invention, can be used to perform detection or diagnosis by distinguishing Parkinson's disease patient groups through a simple blood test. Furthermore, by primarily applying same to patients showing prodromal symptoms of Parkinson's disease, such as olfactory dysfunction, sleep disorders, and constipation, the composition and the diagnostic kit can be used as a preliminary test to determine whether to perform neurological examinations and brain imaging tests at large hospitals. Also, the composition and the diagnostic kit can be used as a means for quantifying the effect of treating Parkinson's disease.
Resumen de: WO2024216192A1
A method is for modulating tight junction (TJ) integrity in a subject. The method includes (a) assessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering to the subject a first composition containing (i) at least one polyphenol, and (ii) a second substance which is not a polyphenol and which upregulates CAMP gene expression in the subject; (c) reassessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of said at least one biomarker is within a target range.
Resumen de: WO2024209449A1
The present disclosure provides a method for detecting a target analyte in a sample, the method comprising: a) providing a quantity of magnetisable particles having a reference magnetic signal that is known or measured before or after the sample is added, the particles being coated with binding molecules complementary to the target analyte, b) bringing the sample comprising the target analyte into contact with the magnetisable particles resulting in bound and unbound binder complexes, c) applying a magnetic field to the sample for a period of time, d) obtaining a magnetic signal, the magnetic signal being the magnetic signal of the bound and unbound binder complexes in the presence of the magnetic field, e) removing the magnetic field for a period of time, and f) comparing the reference magnetic signal and the magnetic signals, wherein a difference between the reference magnetic signal and the magnetic signal correlates to the presence and/or quantity of the target analyte in the sample.
Resumen de: WO2024209075A1
The present disclosure relates to methods of identifying subjects likely to respond to treatment with a myeloperoxidase (MPO) inhibitor based on their neutrophil levels and/or the concentration of at least one protein biomarker. The present disclosure also relates to methods of selecting subjects for treatment with an MPO inhibitor, methods of predicting whether a subject will respond to treatment with an MPO inhibitor and methods of treating subjects likely to respond to treatment with an MPO inhibitor. The present disclosure also relates to a method of predicting an improved clinical response in a subject having an MPO-related disorder following treatment with an MPO inhibitor.
Resumen de: WO2026090347A1
Devices and systems for detecting and quantifying one or more targeted analytes within a biofluid (such as urine) are provided. Such devices and systems can be affixed to or embedded in a garment such as a diaper and are autonomous, noninvasive, and provide quick and accurate results. Methods for using such devices and systems to detect and/or quantify one or more targeted analytes are also provided.
Resumen de: US20260115323A1
The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress/eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress/eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoid
Resumen de: US20260118304A1
This invention introduces an advanced odor detection and classification system that integrates optical and conductive sensors with artificial intelligence for precise, real-time identification of odor profiles across diverse fields. The system employs a colorimetric sensor to capture CIELAB values and a conductive sensor to measure voltage, with data processed through a Neural Network model. This model is trained on an extensive dataset to recognize and predict odors, adapting to variations in odor intensity for enhanced accuracy. Designed for high selectivity, stability, and resilience to environmental factors, the system is ideal for applications in medical diagnostics, food quality control, environmental monitoring, and industrial safety.
Resumen de: WO2026090007A2
In one aspect disclosed herein is a method comprising: coupling a biomolecule to a surface; detecting the biomolecule using surface-enhanced Raman spectroscopy (SERS); and based at least in part on the detecting in b), identifying the biomolecule at an accuracy of at least 75%. In another aspect disclosed herein is a method comprising: coupling an analyte on a surface; detecting the analyte using surface-enhanced Raman spectroscopy (SERS) to obtain analyte data; and identifying the analyte by applying a trained machine learning algorithm to the analyte data, wherein the trained machine learning algorithm does not comprise comparing the analyte data to a database comprising data associated with a reference molecule.
Resumen de: WO2026088136A1
The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.
Resumen de: WO2026088719A1
Provided are: a method for measuring one or more biomarkers to simply and accurately diagnose diseases associated with changes in the activities of cytochrome P450 metabolic enzymes (hereinafter referred to as "P450s"); and a method for detecting the one or more biomarkers. The methods focus on luminescence-based detection of the enzymatic activities of P450s, and involves reacting one or more P450s present in a sample collected in a low- or non-invasive manner, such as serum or urine, with a precursor of a luminescent/light-emitting substrate, metabolizing a luminescent substrate converted from the precursor to generate luminescence, and measuring the generated luminescence. Since many molecular species of P450s are known, the activities of different molecular species of P450s can be measured for each disease on the basis of luminescence intensity, and the activity pattern of each P450 can be analyzed to detect one or more biomarkers.
Resumen de: WO2026089449A1
The present invention relates to a reporter system capable of more accurately and sensitively analyzing autophagy activation on the basis of an autophagy reporter including an ATG4B cleavage site than existing systems, a method for screening an anti-aging or senile disease regulator using same, and a cell line and an animal model expressing the system.
Nº publicación: WO2026090056A1 30/04/2026
Solicitante:
SENGENICS CORP LLC [US]
SENGENICS CORPORATION LLC
Resumen de: WO2026090056A1
Methods of citrullinating one or more proteins by contacting them with protein-arginine deiminase (PAD) in a reaction buffer having a concentration of free-calcium ions below 2mM and a concentration of free-bicarbonate ions above 10 mM, related protein arrays of citrullinated proteins, assay kits and related methods.
BOPI
Sede Electrónica
